Pipettes in a lab

Natalizumab

Natalizumab (Tysabri) is already licensed to treat highly active relapsing MS. It's been trialled for people with progressive MS.

Current phase of trial: Phase 2/3.

Type of MS: Primary and secondary progressive MS

Find out more about natalizumab